<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240148</url>
  </required_header>
  <id_info>
    <org_study_id>D3780C00005</org_study_id>
    <nct_id>NCT01240148</nct_id>
  </id_info>
  <brief_title>Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of AZD3161 on mechanical pain
      sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Results of mechanical pain testing using Quantitative Sensory Testing</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Range of 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Day 1</time_frame>
    <description>(blood pressure, heart rate, pulse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry (urinalysis, hematology)</measure>
    <time_frame>At follow up (a range of 8-15 days after Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of AZD3161 on axon reflex flare in normal and UVC irradiated skin using a Laser doppler scan</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Peripheral Neuropathic Pain</condition>
  <condition>Nociceptive Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 μL intradermal injection of 1 μmol/L AZD3161</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 μL intradermal injection of 6 μmol/L AZD3161</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 μL intradermal injection of 30 μmol/L AZD3161</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 μL intradermal injection of 10 mg/mL Lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 μL intradermal injection of AZD3161 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3161</intervention_name>
    <description>Single dose, intradermal injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Single dose, intradermal injection</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3161 Placebo</intervention_name>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian male and female volunteers aged 18 to 55 years inclusive with
             suitable veins for venepuncture

          -  The subject belongs to skin type II or III according to Fitzpatrick skin type scale

          -  Females must have a negative pregnancy test at screening and at admission, must not be
             lactating and must be of non-child-bearing potential

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh between 50 kg
             and 100 kg inclusive

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the day
             of dosing until 3 months after dosing with investigational product.

        Exclusion Criteria:

          -  Presence of skin disorders, tattoos or other skin conditions that may interfere with
             the QST measurements, as judged by the Investigator

          -  Recent exposure to significant amount of UV light, as judged by the Investigator.

          -  Use of any prescribed or non-prescribed analgesics (including
             paracetamol/acetaminophen or drugs affecting blood flow (including nasal
             anticongestants), prior to the first administration of investigational product that
             may interfere with the study objectives.

          -  History of severe allergy/hypersensitivity, or ongoing allergy/hypersensitivity as
             judged by the Investigator, or history of hypersensitivity to drugs with a similar
             chemical structure or class to AZD3161.

          -  Plasma donation within 1 month of screening or any blood donation/blood loss &gt;500 mL
             during the 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Wilbraham, MD, MBBS DCPSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Allodynia</keyword>
  <keyword>hyperalgesia</keyword>
  <keyword>paresthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

